市場調查報告書
商品編碼
1065887

癌症免疫療法的全球市場:產業趨勢,佔有率,規模,成長,機會,預測(2022年∼2027年)

Cancer Immunotherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

出版日期: | 出版商: IMARC Services Private Limited | 英文 143 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球癌症免疫療法的市場規模,2021年為966億美金,2022年∼2027年之間預計以9.10%的年複合成長率成長,至2027年達到1,675億美元。

全球的癌症患者數增加和醫療產業的急速成長,成為促進市場成長的重要要素之一。還有多發性骨髓瘤和黑色素瘤增加,主要企業的低收入者用患者支援計劃(PAP)和擴大現有處方藥的保險適用的經濟支援,臨床治療的技術進步,廣泛的研究開發活動,提高有效性和治療效果的先進改良型的引進等,也推動市場成長。

本報告提供全球癌症免疫療法市場相關調查分析,市場概要,各市場區隔、各地區的市場分析,競爭情形,企業簡介等資訊。

目錄

第1章 序文

第2章 範圍與調查手法

第3章 摘要整理

第4章 簡介

第5章 全球癌症免疫療法市場

  • 市場概要
  • 市場成果
  • COVID-19影響

第6章 市場明細:治療的各類型

  • 單株抗體
  • 癌症疫苗
  • 免疫查核點抑制劑
  • 免疫調節劑
  • 其他

第7章 市場明細:各用途

  • 肺癌
  • 乳癌
  • 大腸癌症
  • 黑色素瘤
  • 前列腺癌症
  • 頭頸椎癌症
  • 其他

第8章 市場明細:各終端用戶

  • 醫院
  • 癌症研究中心
  • 診所
  • 其他

第9章 市場明細:各地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 其他
  • 中東、非洲
    • 市場明細:各國

第10章 SWOT分析

第11章 價值鏈分析

第12章 波特的五力分析

第13章 價格分析

第14章 競爭情形

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck KGAA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Seagen Inc.
目錄
Product Code: SR0322A157_Report

The global cancer immunotherapy market reached a value of US$ 96.6 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 167.5 Billion by 2027 exhibiting a CAGR of 9.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Cancer is a preventable disease starting in any organ or tissue of the body on account of the abnormal cell growth that invades adjoining parts of the body and spreads to other organs. It is one of the leading causes of death globally, which is nowadays treated using cancer immunotherapy. Cancer immunotherapy offers more advantages than conventional anti-tumor therapy that can prolong progression-free survival (PFS) and overall survival (OS). It can be combined with radiation, chemotherapy, surgery, or targeted therapies to improve their effectiveness. Apart from this, as it enables the immune system to recognize, prevent, control, and eliminate cancer, cancer immunotherapy finds extensive applications in hospitals, cancer research centers, and clinics around the world.

Cancer Immunotherapy Industry Trends and Drivers:

  • There is currently an increase in the number of people who have cancer across the globe. This, in confluence with the burgeoning healthcare industry, represents one of the key factors propelling the growth of the market. Moreover, there are fewer side effects associated with cancer immunotherapy. As a result, there is a significant rise in the use of monoclonal antibodies to treat different types of cancer by selectively attacking cancerous cells. This, coupled with the rising prevalence of multiple myeloma and melanoma, is catalyzing the demand for cancer immunotherapy. Besides this, leading players are sponsoring patient assistance programs (PAPs) that provide financial assistance to low-income individuals for augmenting the existing prescription drug coverage. This, in turn, is positively influencing the market. Other factors strengthening the growth of the market are technological advancements in clinical therapies, extensive research and development (R&D) activities, and the introduction of advanced variants with enhanced efficacy and effectiveness of treatment.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer immunotherapy market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on therapy type, application and end user.

Breakup by Therapy Type:

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators
  • Others

Breakup by Application:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Others

Breakup by End User:

  • Hospitals
  • Cancer Research Centers
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, and Seagen Inc. Key Questions Answered in This Report:

  • How has the global cancer immunotherapy market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global cancer immunotherapy market?
  • What are the key regional markets?
  • What is the breakup of the market based on the therapy type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cancer immunotherapy market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Immunotherapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Checkpoint Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunomodulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Breast Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Colorectal Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Melanoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Prostate Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Head and Neck Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cancer Research Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GlaxoSmithKline Plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Johnson & Johnson
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck KGAA
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Sanofi
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Seagen Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Immunotherapy Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Immunotherapy Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Cancer Immunotherapy Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 4: Global: Cancer Immunotherapy Market: Breakup by Therapy Type (in %), 2021
  • Figure 5: Global: Cancer Immunotherapy Market: Breakup by Application (in %), 2021
  • Figure 6: Global: Cancer Immunotherapy Market: Breakup by End User (in %), 2021
  • Figure 7: Global: Cancer Immunotherapy Market: Breakup by Region (in %), 2021
  • Figure 8: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 9: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 10: Global: Cancer Immunotherapy (Cancer Vaccines) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 11: Global: Cancer Immunotherapy (Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 12: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 13: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 14: Global: Cancer Immunotherapy (Immunomodulators) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 15: Global: Cancer Immunotherapy (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 16: Global: Cancer Immunotherapy (Other Therapy Types) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 17: Global: Cancer Immunotherapy (Other Therapy Types) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 18: Global: Cancer Immunotherapy (Lung Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 19: Global: Cancer Immunotherapy (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 20: Global: Cancer Immunotherapy (Breast Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 21: Global: Cancer Immunotherapy (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 22: Global: Cancer Immunotherapy (Colorectal Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 23: Global: Cancer Immunotherapy (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 24: Global: Cancer Immunotherapy (Melanoma) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 25: Global: Cancer Immunotherapy (Melanoma) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 26: Global: Cancer Immunotherapy (Prostate Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 27: Global: Cancer Immunotherapy (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 28: Global: Cancer Immunotherapy (Head and Neck Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 29: Global: Cancer Immunotherapy (Head and Neck Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 30: Global: Cancer Immunotherapy (Other Applications) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 31: Global: Cancer Immunotherapy (Other Applications) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 32: Global: Cancer Immunotherapy (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 33: Global: Cancer Immunotherapy (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 34: Global: Cancer Immunotherapy (Cancer Research Centers) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 35: Global: Cancer Immunotherapy (Cancer Research Centers) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 36: Global: Cancer Immunotherapy (Clinics) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 37: Global: Cancer Immunotherapy (Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 38: Global: Cancer Immunotherapy (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 39: Global: Cancer Immunotherapy (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 40: North America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 41: North America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 42: United States: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 43: United States: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 44: Canada: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 45: Canada: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 46: Asia-Pacific: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 47: Asia-Pacific: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 48: China: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 49: China: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 50: Japan: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 51: Japan: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 52: India: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 53: India: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 54: South Korea: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 55: South Korea: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 56: Australia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 57: Australia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 58: Indonesia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 59: Indonesia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 60: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 61: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 62: Europe: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 63: Europe: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 64: Germany: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 65: Germany: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 66: France: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 67: France: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 68: United Kingdom: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 69: United Kingdom: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 70: Italy: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 71: Italy: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 72: Spain: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 73: Spain: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 74: Russia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 75: Russia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 76: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 77: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 78: Latin America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 79: Latin America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 80: Brazil: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 81: Brazil: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 82: Mexico: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 83: Mexico: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 84: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 85: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 86: Middle East and Africa: Cancer Immunotherapy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 87: Middle East and Africa: Cancer Immunotherapy Market: Breakup by Country (in %), 2021
  • Figure 88: Middle East and Africa: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 89: Global: Cancer Immunotherapy Industry: SWOT Analysis
  • Figure 90: Global: Cancer Immunotherapy Industry: Value Chain Analysis
  • Figure 91: Global: Cancer Immunotherapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Immunotherapy Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Cancer Immunotherapy Market Forecast: Breakup by Therapy Type (in Million US$), 2022-2027
  • Table 3: Global: Cancer Immunotherapy Market Forecast: Breakup by Application (in Million US$), 2022-2027
  • Table 4: Global: Cancer Immunotherapy Market Forecast: Breakup by End User (in Million US$), 2022-2027
  • Table 5: Global: Cancer Immunotherapy Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 6: Global: Cancer Immunotherapy Market: Competitive Structure
  • Table 7: Global: Cancer Immunotherapy Market: Key Players